| A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) (NCT07483632) | Biogen | 2026-11-16 |
| A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies (NCT06628687) | Biogen | 2026-10-26 |
| A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (NCT07444450) | Biogen | 2026-09-04 |
| A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old (NCT07722546) | Biogen | 2026-07-30 |
| A Study to Learn More About the Safety of a Single Dose of BIIB144 and How it is Processed in the Body of Healthy Adult Participants Ages 18 to 55 Years Old as Compared to a Placebo (NCT07662148) | Biogen | 2026-07-21 |
| A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA) (NCT07221669) | Biogen | 2026-04-28 |
| A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) (NCT07444489) | Biogen | 2026-04-16 |
| A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam (NCT07444476) | Biogen | 2026-04-03 |
| A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation (NCT07219043) | Biogen | 2026-01-05 |
| A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS) (NCT07259980) | Biogen | 2026-01-02 |
| A Long-Term Study of Patient-Reported Changes in Postpartum Depression Symptoms in People Starting Zuranolone (NCT07398469) | Biogen | 2025-12-22 |
| A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants (NCT07225517) | Biogen | 2025-12-18 |
| A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55 (NCT07297199) | Biogen | 2025-12-12 |
| A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55 (NCT07149415) | Biogen | 2025-09-02 |
| A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old (NCT07133828) | Biogen | 2025-08-29 |
| A Study to Learn More About How Zuranolone Affects Postpartum Depression Symptoms in Participants Who Took it Within 1 Year After The End of Their Pregnancy (NCT07047820) | Biogen | 2025-06-30 |
| A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia (NCT06953583) | Biogen | 2025-06-09 |
| A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) (NCT06962800) | Biogen | 2025-05-22 |
| A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) (NCT06935357) | Biogen | 2025-05-08 |
| A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) (NCT06555419) | Biogen | 2025-01-16 |
| A Study to Find Out How Litifilimab is Processed in the Body in Healthy Participants When Given Under the Skin in 3 Different Ways (NCT06741657) | Biogen | 2025-01-02 |
| A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors (NCT06623890) | Biogen | 2024-12-12 |
| A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) (NCT06685757) | Biogen | 2024-12-03 |
| A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk (NCT06612879) | Biogen | 2024-10-18 |
| A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants (NCT06574828) | Biogen | 2024-08-29 |
| A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (NCT06054893) | Biogen | 2024-07-01 |
| A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS) (NCT05767736) | Biogen | 2024-06-08 |
| A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (NCT06311786) | Biogen | 2024-04-08 |
| A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well (NCT05764122) | Biogen | 2024-03-29 |
| A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants (NCT06264440) | Biogen | 2024-02-12 |
| A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants (NCT06262477) | Biogen | 2024-01-02 |
| A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies (NCT05789758) | Biogen | 2023-12-15 |
| A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments (NCT06127095) | Biogen | 2023-11-24 |
| Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate) (NCT05658497) | Biogen | 2023-10-27 |
| A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (NCT06044337) | Biogen | 2023-10-03 |
| A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (NCT05798520) | Biogen | 2023-07-25 |
| A TQTc Study for Omaveloxolone (NCT05927649) | Biogen | 2023-07-11 |
| An Open-label DDI Study of Omaveloxolone in Healthy Subjects (NCT05909644) | Biogen | 2023-07-05 |
| A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS) (NCT05925049) | Biogen | 2023-06-30 |
| A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China (NCT05658484) | Biogen | 2023-06-09 |
| Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD) (NCT05655507) | Biogen | 2023-04-19 |
| 802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia (NCT03070132) | Biogen | 2023-04-19 |
| 802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia (NCT03637387) | Biogen | 2023-03-01 |
| A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants (NCT05701423) | Biogen | 2023-02-08 |
| A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) (NCT05532163) | Biogen | 2023-01-23 |
| Adult Spinal Muscular Atrophy (SMA) China Registry (NCT05618379) | Biogen | 2023-01-06 |
| A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec (NCT05575011) | Biogen | 2022-10-10 |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (NCT05531565) | Biogen | 2022-09-13 |
| A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (NCT05418673) | Biogen | 2022-08-26 |
| A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (NCT05399888) | Biogen | 2022-08-24 |
| A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease (NCT05310071) | Biogen | 2022-06-02 |
| A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis (NCT05265728) | Biogen | 2022-04-26 |
| A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 (NCT05348785) | Biogen | 2022-04-19 |
| A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants (NCT05229562) | Biogen | 2022-02-17 |
| A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular Disorders (NCT05109637) | Biogen | 2022-02-10 |
| A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3 (NCT05160558) | Biogen | 2022-02-02 |
| A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers (NCT05216887) | Biogen | 2022-02-01 |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants (NCT05195008) | Biogen | 2022-01-24 |
| A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) (NCT05067790) | Biogen | 2022-01-21 |
| A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants (NCT05152485) | Biogen | 2021-12-15 |
| Exploring Diroximel Fumarate Real-world Experience in Canada and Israel (NCT04948606) | Biogen | 2021-12-09 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants (NCT05127564) | Biogen | 2021-12-03 |
| A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants (NCT05148481) | Biogen | 2021-11-23 |
| An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US (NCT05097131) | Biogen | 2021-11-18 |
| A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS) (NCT05083923) | Biogen | 2021-11-18 |
| Pediatric Spinal Muscular Atrophy (SMA) China Registry (NCT05042921) | Biogen | 2021-11-18 |
| A Study for Tysabri Participant Preference (NCT05304520) | Biogen | 2021-10-12 |
| A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies (NCT05688436) | Biogen | 2021-09-24 |
| An Observational Study Using Multimodal Sensors to Measure Cognitive Health in Adults and Distinguish Mild Cognitive Impairment From Normal Aging (NCT05058950) | Biogen | 2021-09-20 |
| A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy (NCT04924153) | Biogen | 2021-08-17 |
| A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects (NCT05005338) | Biogen | 2021-07-28 |
| A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (NCT04961567) | Biogen | 2021-07-16 |
| Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (NCT04079088) | Biogen | 2021-06-30 |
| A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers (NCT04924140) | Biogen | 2021-06-30 |
| A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus (NCT04895241) | Biogen | 2021-05-25 |
| A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (NCT04856982) | Biogen | 2021-05-17 |
| Study to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support Program (NCT04655222) | Biogen | 2021-04-30 |
| A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD) (NCT04729907) | Biogen | 2021-04-19 |
| Real World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by Tecfidera (NCT04756687) | Biogen | 2021-03-10 |
| Study of Diroximel Fumarate in the Real-World Setting (NCT04746976) | Biogen | 2021-03-01 |
| A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN) (NCT04702997) | Biogen | 2021-02-09 |
| A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND) (NCT04488133) | Biogen | 2021-01-04 |
| A Study to Assess Choroideremia (CHM) Health Outcomes (NCT04750785) | Biogen | 2020-12-15 |
| MS PATHS COVID-19 Questionnaire Data Linkage Sub-Study (NCT05058729) | Biogen | 2020-12-07 |
| Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection (NCT04419233) | Biogen | 2020-11-18 |
| A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder (NCT04476030) | Biogen | 2020-11-09 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants (NCT04593121) | Biogen | 2020-10-30 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants (NCT04571424) | Biogen | 2020-10-14 |
| Validation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple Sclerosis (NCT04756700) | Biogen | 2020-10-12 |
| Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy (NCT04106050) | Biogen | 2020-09-30 |
| Study of BIIB091 Formulations in Healthy Participants (NCT04564612) | Biogen | 2020-09-28 |
| A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (NCT04494256) | Biogen | 2020-09-28 |
| Natural Disease Progression in Participants With Choroideremia (NCT04795206) | Biogen | 2020-08-26 |
| A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD) (NCT04442503) | Biogen | 2020-06-08 |
| A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD) (NCT04442490) | Biogen | 2020-05-12 |
| Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS) (NCT04288856) | Biogen | 2020-04-28 |
| Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy (NCT04089566) | Biogen | 2020-03-26 |
| A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (NCT04241068) | Biogen | 2020-03-02 |
| A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants (NCT04068532) | Biogen | 2019-11-15 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis (NCT03958877) | Biogen | 2019-10-18 |